Cancer Research

Antibodies attacking cancer cell
#Bispecific Antibodies #Cancer research #Cancer treatment #Mergers and acquisitions #Monoclonal antibodies #Oncology

Jazz acquires rights to HER2-targeted bispecific antibody

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential… Read More

#Cancer Research #News

Protein molecule
#Biomarkers #Cancer #Diagnostics #Precision medicine #Proteomics

South Korean proteomics company Bertis expands to the US

Bertis, a South Korean proteomics-based precision medicine technology company, has established a US-based wholly-owned entity to expand its global presence. The subsidiary, called Bertis Bioscience, aims to establish a San Diego-based CLIA-certified lab facility in early Q4, 2022. It will offer proteomics-based screening and diagnostic tests, as well as an… Read More

#Cancer Research #News

Wear it Pink
#Breast cancer #Breast Cancer Now #Cancer research #Chemotherapy #Chemotherapy-resistance #Drug discovery #Oncology #Tumours

Five breakthroughs advancing breast cancer therapies

Not only is October Breast Cancer Awareness Month but October 21 is Wear it Pink 2022, Breast Cancer Now’s annual fundraising day. While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US1),… Read More

#Cancer Research #News #Trending News

RNA vaccine
#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA

Merck and Moderna to develop personalised cancer vaccine

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck… Read More

#Cancer Research #News #Trending News

Cancer research in lab
#Cancer research #Collaboration #Genomics #Oncology

Strategic collaboration to enhance targeted oncology programmes

Oncology platform company Tavros Therapeutics and biopharmaceutical company Vividion Therapeutics (a subsidiary of Bayer AG) have agreed to collaborate on four oncology targets across an initial five-year term. Tavros’ functional and computational genomics technologies are designed to uncover unique vulnerabilities within tumours to discover novel targets and biomarkers in areas… Read More

#Business & Investment #Cancer Research #News

Breast cancer
#Breast cancer #Breast Cancer Now #Cancer immunotherapy #Cancer research #King's College London #Oncology #The Institute of Cancer Research

Immune targets identified for chemo-resistant breast cancers

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery. The research gives insight… Read More

#Cancer Research #News

#Cancer research #Cancer Research Horizons #Cancer Research UK #Drug development #Drug discovery #Oncology

New horizon for cancer innovation

Listen to this article on the DDW podcast: Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of… Read More

#Cancer Research #Exclusive Content

Melanoma or skin cancer
#Immuno-oncology #Melanoma #Oncology

T cell therapy for melanoma shows promise 

New trial data has shown that using a patient’s own immune cells could be a powerful immunotherapy for metastatic melanoma, an aggressive skin cancer.  The TIL (tumour-infiltrating lymphocytes) trial compared T cell therapy to standard immunotherapy with the checkpoint inhibitor ipilimumab.  The results of the… Read More

#Cancer Research #News

Cancer cells
#Cancer research #mRNA #Wellcome Sanger Institute

Study develops new way of identifying cancer cells  

A new method of separating cancer cells from non-cancer cells has been developed by researchers at the Wellcome Sanger Institute, in a boost for those working to better understand cancer biology using single-cell mRNA sequencing.  The study, published in Communications Biology, improves on existing methods to identify… Read More

#Cancer Research #News

Melanoma
#Cancer research #Melanoma #Skin cancer

Researchers slow down spread of melanoma 

Scientists from Tel Aviv University have deciphered the mechanism that enables skin cancer to metastasise to the brain and were able to delay the spread of the disease by 60-80% using existing treatments.  Once melanoma, or skin cancer, spreads to the brain, it becomes extremely aggressive. Patients… Read More

#Cancer Research #News

Herpes virus cells
#Cancer research #Cancer treatment #Herpes virus #Immunotherapy #Oncology #The Institute of Cancer Research

Researchers successfully exploit virus against advanced cancers

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of… Read More

#Cancer Research #News #Trending News

Breast cancer cells
#Breast cancer #Cancer research #Oncology

Breast cancer cells ‘regulate their own metastases’

Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies. This phenomenon then leads to later metastatic breast cancer in patients who have been cancer-free for years. According to a study published… Read More

#Cancer Research #News

Colorectal cancer
#Cancer research #Colorectal cancer #Oncology

Trial sheds light on combined treatment for colorectal cancer

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone. The Phase III clinical trial studied participants with… Read More

#Cancer Research #News

#Biomarkers #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research

NICE rejects prostate cancer drug due to cost of genetic testing

The National Institute of Health and Care Excellence (NICE) has confirmed its decision not to recommend olaparib for previously treated metastatic prostate cancer in patients with BRCA gene mutations. The Institute of Cancer Research (ICR) has called the decision ‘disappointing’ and ‘frustrating’. It means that men in England and Wales… Read More

#Cancer Research #News #Trending News